<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Transfusion in sickle cell disease: Management of complications including iron overload
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Transfusion in sickle cell disease: Management of complications including iron overload
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Transfusion in sickle cell disease: Management of complications including iron overload
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael R DeBaun, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stella T Chou, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elliott P Vichinsky, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2700576247">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with sickle cell disease (SCD) have chronic anemia that can worsen abruptly for various reasons such as splenic sequestration or transient red cell aplasia, and they are at risk of vaso-occlusive events, including stroke, due to the high concentration of sickle hemoglobin (Hb S) associated with their condition. Transfusion of red blood cells (RBCs) can be life-saving in these settings.
        </p>
        <p>
         Blood transfusion carries risks, many of which, especially alloimmunization and excess iron stores, are more likely and are typically more severe in individuals with SCD than in the general population. Excessive accumulation of iron is a serious problem that may not be detected because transfusion therapy may be irregular and episodic. The approach to transfusion must balance these benefits and risks, both in decisions regarding when to transfuse and in the practical aspects of how transfusions are administered.
        </p>
        <p>
         Here we discuss complications of transfusion unique to this population, including high rates of alloimmunization and iron overload.
        </p>
        <p>
         Separate topic reviews present an overview of the indications for transfusion and transfusion techniques in SCD, RBC antigens, and the general evaluation and management of transfusion reactions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Indications and techniques in SCD – (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RBC antigens – (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation of an acute transfusion reaction – (See
         <a class="medical medical_review" href="/z/d/html/95132.html" rel="external">
          "Approach to the patient with a suspected acute transfusion reaction"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transfusion-associated circulatory overload – (See
         <a class="medical medical_review" href="/z/d/html/7919.html" rel="external">
          "Transfusion-associated circulatory overload (TACO)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transfusion-related acute lung injury – (See
         <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">
          "Transfusion-related acute lung injury (TRALI)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemolytic transfusion reactions – (See
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allergic, anaphylactic, and febrile nonhemolytic reactions – (See
         <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">
          "Immunologic transfusion reactions"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transfusion-transmitted bacterial infection – (See
         <a class="medical medical_review" href="/z/d/html/3805.html" rel="external">
          "Transfusion-transmitted bacterial infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3277118410">
         <span class="h1">
          LIMITING TRANSFUSIONS TO APPROPRIATE USE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications can be reduced by limiting transfusions to the appropriate clinical indications and using appropriate techniques, which are summarized here and discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Indications for transfusion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H413129775">
         <span class="h2">
          Appropriate indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use red cell transfusion in clinical scenarios where there is strong or compelling evidence of the benefit of reduced morbidity. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Indications for transfusion'
         </a>
         .)
        </p>
        <p>
         Transfusions are used acutely for the treatment of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemodynamic compromise
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute chest syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute cerebral infarction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient ischemic attack
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple organ failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An acute drop in hemoglobin without reticulocytosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute hepatic or splenic sequestration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Priapism, if a urological procedure fails to produce detumescence
        </p>
        <p>
        </p>
        <p>
         Transfusions are used prophylactically during pregnancy, perioperatively, and to reduce incidence of a range of vaso-occlusive complications of SCD including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stroke
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Silent cerebral infarcts
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent acute chest syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vaso-occlusive pain episodes that are severe and do not respond to medical therapies
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent priapism
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary hypertension with progression
        </p>
        <p>
        </p>
        <p>
         The most prominent
         <strong>
          misuse
         </strong>
         of blood transfusion therapy is simple transfusion in an adult or child with SCD admitted to the hospital for an uncomplicated vaso-occlusive pain episode without symptomatic anemia or vaso-occlusive pain without a significant change from the individual's baseline hemoglobin (typically &lt;2 g/dL). In such a situation, there is no evidence that simple transfusion therapy will abate the pain episode, and there is a finite risk of transfusion-related complications, including the increased risk for alloimmunization [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         For complicated vaso-occlusive pain episodes treated in the hospital, transfusion may be appropriate in the following instances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the hemoglobin has decreased by ≥2 g/dL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The person has developed pneumonia or acute chest syndrome with an increasing oxygen requirement to maintain oxygen saturation greater than 95 percent
        </p>
        <p>
        </p>
        <p>
         In these situations, transfusion is used as an adjunct to (not a substitute for) pain management. (See
         <a class="medical medical_review" href="/z/d/html/110699.html" rel="external">
          "Evaluation of acute pain in sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">
          "Acute vaso-occlusive pain management in sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/126298.html" rel="external">
          "Disease-modifying therapies to prevent pain and other complications of sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3039999234">
         <span class="h2">
          Appropriate techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Appropriate use of red blood cell (RBC) antigen matching and exchange transfusion rather than simple transfusion in certain settings are important for reducing alloimmunization and iron overload, respectively. (See
         <a class="local">
          'Alloimmunization and hemolysis'
         </a>
         below and
         <a class="local">
          'Excessive iron stores'
         </a>
         below.)
        </p>
        <p>
         Details are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'RBC antigen matching'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Simple versus exchange transfusion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2663729005">
         <span class="h1">
          ACUTE TRANSFUSION REACTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         As a general rule, acute transfusion reactions such as febrile nonhemolytic transfusion reactions (FNHTRs) and allergic reactions are low per unit transfusion in patients with SCD, perhaps due to the routine use of leukoreduction in this population and extended phenotypic matching in most institutions.
        </p>
        <p>
         As an example, in the Silent Cerebral Infarct Transfusion (SIT) trial, there were 3236 transfusions administered; of these, nine participants had one reaction, six had two reactions, and one had four reactions [
         <a href="#rid2">
          2
         </a>
         ]. Eight of 3236 transfusions (0.2 percent) were associated with a FNHTR and 13 of 3236 (0.4 percent) with an allergic reaction.
        </p>
        <p>
         Patients with an acute transfusion reaction are generally treated similarly to individuals without SCD. (See
         <a class="medical medical_review" href="/z/d/html/95132.html" rel="external">
          "Approach to the patient with a suspected acute transfusion reaction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1815222451">
         <span class="h2">
          Anaphylactic and allergic reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anaphylactic reactions to red blood cell (RBC) transfusions must be distinguished from severe hemolytic transfusion reactions due to antibodies formed against RBC antigens.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pathogenesis of anaphylactic and allergic reactions includes immune reactions against plasma proteins such as immunoglobulin (Ig) A, which is rare, as well as inflammatory cytokines in the product, passive antibody transfer, or both [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for the underlying cause of an anaphylactic reaction should at least consider IgA deficiency and haptoglobin deficiency if the patient has an anaphylactic reaction [
         <a href="#rid3">
          3
         </a>
         ]. Elevated serum or plasma tryptase levels are supportive of an anaphylactic reaction [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment includes immediate cessation of transfusion and supportive care as needed, which might include oxygen supplementation, airway management, fluid resuscitation or vasopressors for hypotension, antihistamines, and
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         . We are unaware of the benefit of corticosteroids in this situation.
        </p>
        <p>
        </p>
        <p>
         The evaluation and additional management of these reactions is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">
          "Immunologic transfusion reactions", section on 'Anaphylactic transfusion reactions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">
          "Immunologic transfusion reactions", section on 'Allergic reactions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3557336088">
         <span class="h2">
          Potential concerns about meperidine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          Meperidine
         </a>
         can sometimes be used to treat transfusion-associated rigors, which can be severe and may make the patient, family, or caregivers very uncomfortable. Short-term use of meperidine (&lt;24 hours) to treat rigors is acceptable, as long as the patient has normal kidney function and no previous history of seizures [
         <a href="#rid4">
          4,5
         </a>
         ]. However, meperidine is metabolized to normeperidine, which has a half-life of 18 hours. When used for multiple days, normeperidine can cause anxiety, tremors, myoclonus, and seizures [
         <a href="#rid4">
          4,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">
          "Acute vaso-occlusive pain management in sickle cell disease", section on 'Therapies we do not use'
         </a>
         .)
        </p>
        <p>
         Rather than using
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         , which is sedating, we use a nonsedating histamine 1 (H1)-receptor antagonist to treat an acute reaction with rigors. (See
         <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">
          "Immunologic transfusion reactions", section on 'Febrile nonhemolytic transfusion reactions'
         </a>
         .)
        </p>
        <p>
         Rigors associated with FNHTR are acute and self-limited; if there are any signs that suggest possible bacterial infection, the patient should be evaluated and treated accordingly, as patients with SCD are functionally asplenic and at risk of serious morbidities and mortality from sepsis. (See
         <a class="medical medical_review" href="/z/d/html/5937.html" rel="external">
          "Evaluation and management of fever in children and adults with sickle cell disease", section on 'Risk of life-threatening infection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3805.html" rel="external">
          "Transfusion-transmitted bacterial infection", section on 'Immediate interventions'
         </a>
         .)
        </p>
        <p>
         In contrast to using a single dose of
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         for rigors, we avoid meperidine for treating acute vaso-occlusive pain events in SCD because of potential toxicities of use for &gt;24 to 48 hours (due to production of a toxic metabolite, normeperidine).
        </p>
        <p class="headingAnchor" id="H4222146246">
         <span class="h1">
          ALLOIMMUNIZATION AND HEMOLYSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with SCD have a high risk of alloimmunization (development of antibodies to red blood cell [RBC] antigens) typically due to a mismatch in minor RBC antigens between the donor pool and patients with SCD. The higher rate of alloimmunization can lead to difficulty in future crossmatching, which in turn reduces eligibility for chronic transfusion therapy and decreases access to compatible blood needed in the treatment of acute events [
         <a href="#rid7">
          7
         </a>
         ]. Alloimmunization can also lead to hemolytic transfusion reactions if the implicated antigen is not excluded from future transfusions.
        </p>
        <p class="headingAnchor" id="H2627568043">
         <span class="h2">
          Likelihood of alloimmunization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Standard transfusion practice includes crossmatching RBC units for ABO and RhD antigens. (See
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion", section on 'Compatibility testing (crossmatch)'
         </a>
         .)
        </p>
        <p>
         As discussed separately, matching for additional Rh antigens (C, E, or C/c, E/e) and the Kell blood group antigen K is also recommended for individuals with SCD and has been demonstrated to reduce alloimmunization rates significantly [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'RBC antigen matching'
         </a>
         .)
        </p>
        <p>
         Direct comparison of the prevalence of alloimmunization in individuals with and without SCD is challenging because individuals with SCD receive more blood transfusions compared to individuals without SCD. Individuals with SCD are one of the most frequently transfused and heavily alloimmunized groups of patients, with the prevalence ranging from 7 to 59 percent Patients with SCD are one of the most frequently transfused and heavily alloimmunized groups of patients, with the prevalence ranging from 7 to 59 percent [
         <a href="#rid7">
          7,9
         </a>
         ]. This compares with a prevalence of 2 to 3 percent of transfused patients in general hospital populations [
         <a href="#rid10">
          10,11
         </a>
         ]. In the absence of Rh (C, E or C/c, E/e) and K antigen matching, alloimmunization occurs in approximately 30 percent of individuals with SCD who are transfused at least intermittently [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Instead of the prevalence of alloimmunization, the incidence rate of new alloantibodies per 100 units of RBCs transfused should be used, so that reasonable comparisons can be made from one study to another. Even when using the alloimmunization incidence per 100 units of RBCs, the true incidence may be biased unless the entire transfusion history is taken into account. Two randomized controlled trials conducted in children with SCD provided an estimate of the alloimmunization incidence rates, because relatively few children received transfusions prior to the entry into the trial, and the trial protocols intended for all units to be matched for Rh antigens C and E, and Kell antigen K:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the SIT Trial, in which children with silent cerebral infarcts were randomly allocated to receive regular blood transfusion therapy or standard care for three years of observation, a total of 3236 transfusions were administered in the transfusion group, and nine alloantibodies were detected in four participants: anti-C (in two participants), anti-V (in two participants), anti-FyA, anti-e, anti-S, anti-Jk
         <sup>
          b
         </sup>
         , and anti-Wra, for an alloimmunization rate of 0.278 per 100 units of RBCs [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the STOP Trial, in which children with abnormal transcranial Doppler measurements were randomly allocated to receive regular blood transfusions or observation, a total of 1830 units were transfused, and the alloimmunization rate was 0.5 per 100 units of RBCs [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These trials indicate that when RBCs are prophylactically matched at a minimum for C, E, and K, the expected alloimmunization rate is low, between 0.28 and 0.5 per 100 units transfused.
        </p>
        <p class="headingAnchor" id="H3123721140">
         <span class="h2">
          Prevalence of DHTRs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alloimmunization can lead to hemolysis. Typically, this manifests as a delayed hemolytic transfusion reaction (DHTR). (See
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions", section on 'Delayed hemolytic transfusion reactions and delayed serologic transfusion reactions'
         </a>
         .)
        </p>
        <p>
         DHTRs are not always recognized, since their presentations are sometimes subtle. When specifically evaluated, the prevalence of DHTRs in individuals with SCD appears to be between 5 and 10 percent or higher.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2017 prospective study of 694 transfusion episodes in 311 patients over a 30-month period, the incidence of DHTR was approximately 5 percent [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2015 retrospective review of 220 individuals with SCD receiving transfusions over a five-year period, 17 experienced a DHTR (8 percent); this represented 23 of 2158 (1 percent) of transfusions [
         <a href="#rid15">
          15
         </a>
         ]. Of note, 11 of these reactions (48 percent) were not appreciated at the time; most were misdiagnosed as a vaso-occlusive event.
        </p>
        <p>
        </p>
        <p>
         Under-recognition of DHTRs was notable in a 2019 retrospective study in a cohort of 624 transfused individuals with SCD [
         <a href="#rid16">
          16
         </a>
         ]. The study found laboratory evidence of DHTR based on total hemoglobin (Hb) and sickle hemoglobin (Hb S) levels, with 54 of 178 antibodies (30.3 percent); of these, fewer than half were recognized by the patient or provider at the time of the event.
        </p>
        <p>
         The higher frequency of DHTRs in individuals with SCD is thought to primarily be due to the higher frequency of transfusions in which blood group incompatibilities exist between the donor population, which is predominantly White individuals, and the recipient SCD population, which is predominantly of African descent [
         <a href="#rid12">
          12,17,18
         </a>
         ].
        </p>
        <p>
         Antibodies against the Rh (D, C/c, E/e), Kell (K), Duffy (Fy
         <sup>
          a
         </sup>
         , Fy
         <sup>
          b
         </sup>
         ), and Kidd (Jk
         <sup>
          a
         </sup>
         , Jk
         <sup>
          b
         </sup>
         ) antigens present the greatest problem in transfusing these individuals [
         <a href="#rid12">
          12,17,19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Rh antigens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Kidd antigens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Duffy antigens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Kell antigens'
         </a>
         .)
        </p>
        <p>
         This underscores the importance of prophylactic Rh (C, E, or C/c, E/e) and K antigen matching. Finding sufficient compatible donors requires recruitment of donors from the same ethnic backgrounds. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'RBC antigen matching'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2438402935">
         <span class="h2">
          Other forms of immune hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other forms of immune hemolysis can also occur:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoimmune hemolysis
         </strong>
         – Autoantibodies (antibodies that recognize the patient's own RBCs) have been reported in 7 to 47 percent of patients with SCD receiving transfusions [
         <a href="#rid13">
          13,20
         </a>
         ]. An autoantibody is more likely to develop in patients who have already been alloimmunized. Some patients have a nonspecific, transient, weakly positive direct antiglobulin (Coombs) test (DAT) that has no specificity and is not associated with hemolysis. However, a new autoantibody can cause marked hemolysis (albeit rarely) and should undergo reference laboratory evaluation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AHTRs
         </strong>
         – Acute hemolytic transfusion reactions (AHTRs) can also occur. AHTRs are typically caused by clerical error with transfusion of the wrong ABO group blood, but in patients with SCD, these reactions often occur due to antibodies against non-ABO blood group antigens. An AHTR is a medical emergency. (See
         <a class="local">
          'Acute transfusion reactions'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions", section on 'Acute hemolytic transfusion reactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperhemolysis
         </strong>
         – Hyperhemolysis refers to alloimmune hemolysis accompanied by bystander hemolysis of the patient's own RBCs. The mechanism is poorly understood. The degree of hemolysis can be severe. (See
         <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">
          "Overview of the clinical manifestations of sickle cell disease", section on 'Hyperhemolytic crisis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3998741073">
         <span class="h2">
          Clinical features of immune hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         DHTRs generally occur 3 to 14 days after a transfusion. Patients with SCD who develop a DHTR may present with worsening anemia, increased fatigue, jaundice, dark urine, fever, and/or pain [
         <a href="#rid21">
          21,22
         </a>
         ]. Importantly, a DHTR can be difficult to diagnose as the DAT may be negative or weak, and new antibody formation is not always detectable at the time of symptomatic presentation [
         <a href="#rid16">
          16,22,23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions", section on 'Delayed hemolytic transfusion reactions and delayed serologic transfusion reactions'
         </a>
         .)
        </p>
        <p>
         The patient often has pain with evidence of hemolysis but a low reticulocyte count. Hemoglobin analysis typically demonstrates the disappearance of the transfused, Hb A-containing RBCs. Individuals with SCD have hemolysis at baseline, so hemolytic markers may be less helpful, and the evaluation should focus on the identification of new alloantibodies. (See
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion", section on 'Antibody screen'
         </a>
         .)
        </p>
        <p>
         In some cases, Hb analysis may suggest "bystander" hemolysis of the patient's Hb S-containing RBCs, also referred to as hyperhemolysis or hyperhemolytic crisis. Hyperhemolysis events are serious and can be life-threatening [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">
          "Overview of the clinical manifestations of sickle cell disease", section on 'Hyperhemolytic crisis'
         </a>
         .)
        </p>
        <p>
         In some cases, there will be multiple alloantibodies, making it difficult to obtain compatible RBCs for transfusion. In a 2016 analysis of 99 DHTRs in SCD, the overall mortality was 6 percent, and these DHTRs were often associated with pain events and secondary acute chest syndrome [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Symptomatic or severe anemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion", section on 'Sickle cell disease or thalassemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2343501579">
         <span class="h2">
          Evaluation of immune hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Testing for immune hemolysis includes hemoglobin (Hb) quantification, bilirubin, reticulocyte count, and lactate dehydrogenase (LDH). Any patient who has any one or a combination of findings of hemolysis, including a rapid decrease in Hb level and proportion of Hb A after the transfusion, jaundice with increased bilirubin, hemoglobinuria, or increased reticulocyte percentage (
         <a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">
          table 1
         </a>
         ) should be evaluated with a DAT. A low reticulocyte may also be seen [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/95132.html" rel="external">
          "Approach to the patient with a suspected acute transfusion reaction", section on 'Suspected acute hemolytic reaction'
         </a>
         .)
        </p>
        <p>
         Any patient with a positive DAT should undergo evaluation to identify the antibody specificity (antibody identification) to avoid this antigen in future transfusions. Since these events are more likely following transfusion for an acute complication of SCD, any patient who has been recently transfused and presents with symptoms of worsening anemia should be evaluated for a DHTR. (See
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions", section on 'Evaluation of DHTR and DSTR'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H338735606">
         <span class="h2">
          Management of immune hemolysis
         </span>
        </p>
        <p class="headingAnchor" id="H2215225522">
         <span class="h3">
          DHTRs
         </span>
         <span class="headingEndMark">
          —
         </span>
         For an uncomplicated delayed hemolytic transfusion reaction (DHTR), we avoid further transfusion if possible. To manage the DHTR, we provide supportive care with hydration and pain control as needed. (See
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions", section on 'Management of DHTR and DSTR'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110699.html" rel="external">
          "Evaluation of acute pain in sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">
          "Acute vaso-occlusive pain management in sickle cell disease"
         </a>
         .)
        </p>
        <p>
         Hyperhemolysis is a serious but rare complication that may accompany a DHTR (see
         <a class="local">
          'Hyperhemolysis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">
          "Overview of the clinical manifestations of sickle cell disease", section on 'Hyperhemolytic crisis'
         </a>
         ). Since DHTRs with hyperhemolysis are uncommon, the role of immunosuppressive therapy is based on case reports, case series, and expertise. In the event that a patient with SCD and hyperhemolysis requires preparation for hematopoietic stem cell transplant, gene therapy, or gene editing, referral to a transplant center with local expertise in immunosuppressive therapy is appropriate.
        </p>
        <p>
         If additional transfusions are required, at a minimum, the red cells should be matched for ABO, Rh (C, E or C/c, E/e) and K, and RBC units should lack any antigens identified in the DHTR evaluation [
         <a href="#rid8">
          8
         </a>
         ]. We also attempt to provide extended matching for Jk
         <sup>
          a
         </sup>
         /Jk
         <sup>
          b
         </sup>
         , Fy
         <sup>
          a
         </sup>
         /Fy
         <sup>
          b
         </sup>
         , and S/s. However, there should be close communication with the blood bank about the availability of extended antigen-matched units, and any delays in transfusion must be weighed against the patient's clinical status and urgency with which further transfusion is needed. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Indications for transfusion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1355921080">
         <span class="h3">
          Hyperhemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperhemolysis is a potentially life-threatening reaction in which accelerated hemolysis and worsening anemia occur following transfusion. The mechanism is poorly understood. (See
         <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">
          "Overview of the clinical manifestations of sickle cell disease", section on 'Hyperhemolytic crisis'
         </a>
         .)
        </p>
        <p>
         Hyperhemolysis and other severe hemolytic reactions, defined as transfusion-associated hemolysis with a rapid hemoglobin decline to below the pretransfusion level and rapid decline of the post-transfusion Hb A level, require prompt intervention, but evidence to guide optimal therapy is limited [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         We suggest prompt initiation of immunosuppressive therapy for patients with hyperhemolysis with a glucocorticoid, intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), or both, especially for those who require further transfusions. The choice between glucocorticoids, IVIG, or both is individualized [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First-line agents include glucocorticoids (
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         at 1 to 4 mg/kg daily or equivalent dose
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         ) or
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         (0.4 to 1 g/kg per day for three to five days) [
         <a href="#rid8">
          8
         </a>
         ]. Glucocorticoids may be given first and IVIG added if hemolysis is especially severe or continues despite glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence for the benefit of glucocorticoids is largely indirect, based on its efficacy in autoimmune hemolysis (see
         <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">
          "Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Glucocorticoids with or without rituximab as first-line agents'
         </a>
         ) and from small case series or case reports of individuals with SCD showing good outcomes [
         <a href="#rid27">
          27-32
         </a>
         ]. The use of glucocorticoids must be balanced against the known association with severe acute vaso-occlusive pain episodes and possibly fat emboli [
         <a href="#rid33">
          33-37
         </a>
         ]. However, evidence from case reports suggests that hyperhemolysis almost always favors treatment with glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depending on the length of the glucocorticoid therapy, regardless of the dose or duration of glucocorticoids, severe acute vaso-occlusive pain may be temporally related to the administration, typically within five days of treatment [
         <a href="#rid34">
          34,35,38-40
         </a>
         ]. We are unaware of data that indicate whether a slow steroid taper or an abrupt cessation of the steroid will be more likely to reduce the risk of acute rebound vaso-occlusive pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">
          Eculizumab
         </a>
         , a monoclonal antibody that targets the C5 component of complement, is generally reserved as a second-line agent if hemolysis does not respond to glucocorticoids and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         [
         <a href="#rid7">
          7,41-43
         </a>
         ]. Prescribing information for eculizumab carries a Boxed Warning regarding the risk of meningococcal infections and need to vaccinate [
         <a href="#rid44">
          44
         </a>
         ]. The Advisory Committee on Immunization Practices (ACIP) also encourages clinicians to consider anti-meningococcal prophylaxis for the duration of eculizumab treatment [
         <a href="#rid45">
          45
         </a>
         ]. This subject is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">
          "Treatment and prevention of meningococcal infection", section on 'Patients receiving C5 inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients in whom further transfusion is likely,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         can be considered [
         <a href="#rid46">
          46
         </a>
         ]. However, rituximab can produce varying degrees of immunosuppression that may persist beyond the initial course of therapy, which is of potential concern in SCD due to coexisting functional asplenia. (See
         <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">
          "Secondary immunodeficiency induced by biologic therapies", section on 'Rituximab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         , a monoclonal antibody against the IL-6 receptor that blocks macrophage activation, has been described for salvage treatment of severe DHTRs and hyperhemolysis [
         <a href="#rid47">
          47-50
         </a>
         ]. In these reports, administration of one to four doses of 8 mg/kg daily was associated with good clinical responses and evidence of decreased hemolysis. Adverse events were limited to one patient who had seizures; the individual also had methemoglobinemia due to a hemoglobin-based oxygen carrier.
        </p>
        <p>
        </p>
        <p>
         We also administer erythropoietin as a means of reducing the need for further transfusions, although transfusions may be required if the patient is experiencing life-threatening anemia [
         <a href="#rid8">
          8
         </a>
         ]. Case reports and small series have demonstrated erythropoietin to be associated with good outcomes without major serious adverse events [
         <a href="#rid27">
          27,51
         </a>
         ]. Doses in the range of 4000 international units subcutaneously once per day for 7 to 14 days have been used [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="126260" href="/z/d/drug information/126260.html" rel="external">
          Voxelotor
         </a>
         has been used in severe cases (baseline Hb &lt;6 g/dL), but data supporting safety and efficacy are lacking. Voxelotor has also been used in individuals who decline blood transfusion, have a Hb &lt;9 g/dL, and require surgery with general anesthesia [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease", section on 'FDA-approved agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7927.html" rel="external">
          "Approach to the patient who declines blood transfusion", section on 'Jehovah's Witnesses'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H156895167">
         <span class="h1">
          INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consequences of transfusion-related infection may be more serious in individuals with SCD compared to the general population:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Viral infections that may reduce bone marrow production of red blood cells (RBCs) could lead to more severe acute anemia when superimposed on the chronic hemolytic anemia of SCD. In the United States, transfusion-transmission of serious viral infections is very rare except for parvovirus. (See
         <a class="local">
          'Parvovirus'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bacterial infections, especially with encapsulated organisms, poses a greater risk because individuals with SCD are functionally asplenic due to splenic infarction early in life and are at risk for bacterial sepsis. (See
         <a class="local">
          'Bacterial infection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2857367651">
         <span class="h2">
          Parvovirus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parvovirus is not eliminated by standard blood screening, and it is not inactivated by viral inactivation processes used for plasma products (see
         <a class="medical medical_review" href="/z/d/html/7929.html" rel="external">
          "Pathogen inactivation of blood products"
         </a>
         ). Unlike the general population, for whom parvovirus infection often does not cause severe anemia, patients with SCD who are infected with parvovirus can become symptomatic from an acute anemia caused by transient bone marrow red cell aplasia. This is because most individuals in the general population can easily tolerate a brief period of reduced RBC production and can compensate by increasing the reticulocyte count, whereas those with SCD are already in a state of compensated hemolytic anemia and cannot easily increase RBC production in the setting of transiently reduced RBC production. (See
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Transient aplastic crisis'
         </a>
         .)
        </p>
        <p>
         Management of parvovirus-induced anemia is supportive with transfusions as needed. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Symptomatic or severe anemia'
         </a>
         .)
        </p>
        <p>
         The infection typically resolves after several days or in some cases weeks. For the rare patient with chronic infection and chronic hemolysis, intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) can be administered. (See
         <a class="medical medical_review" href="/z/d/html/8330.html" rel="external">
          "Treatment and prevention of parvovirus B19 infection", section on 'Transient aplastic crisis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8330.html" rel="external">
          "Treatment and prevention of parvovirus B19 infection", section on 'Chronic infection with anemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2096443541">
         <span class="h2">
          CMV
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of antibodies to cytomegalovirus (CMV) is a nonspecific assay for CMV infectivity, and 30 to 70 percent of blood donors, depending upon geographic region, test positive for the presence of CMV antibodies. Leukoreduced RBCs also provide "CMV-safe" blood. Leukoreduced blood contains &lt;5 million leukocytes per unit and is routinely performed prestorage with an RBC filter. (See
         <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">
          "Blood donor screening: Laboratory testing", section on 'Cytomegalovirus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Leukoreduction'
         </a>
         .)
        </p>
        <p>
         Prestorage leukoreduction of RBCs is also a means of preventing febrile nonhemolytic transfusion reactions (FNHTRs). (See
         <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">
          "Immunologic transfusion reactions", section on 'Febrile nonhemolytic transfusion reactions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3581004160">
         <span class="h2">
          Other viruses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transfusion transmission of HIV, human T-lymphotropic virus type I (HTLV-I), and hepatitis B and C has diminished markedly with improved screening of banked units of blood (
         <a class="graphic graphic_table graphicRef69661" href="/z/d/graphic/69661.html" rel="external">
          table 2
         </a>
         ). However, individuals with SCD who have immigrated to the United States may have previously received units of blood with the potential to transmit these viruses, and should be screened for viral hepatitis and HIV. (See
         <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">
          "Blood donor screening: Laboratory testing", section on 'Infectious disease screening and surveillance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1600519370">
         <span class="h2">
          Bacterial infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of sepsis from intravenous catheters or transfusion-transmitted bacterial infection (TTBI) can be reduced by appropriate catheter care and disease management that lessens the need for transfusions and limits transfusions to indications for which they are likely to be helpful. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Indications for transfusion'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15671.html" rel="external">
          "Routine care and maintenance of intravenous devices"
         </a>
         .)
        </p>
        <p>
         Evaluation and management of TTBI is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3805.html" rel="external">
          "Transfusion-transmitted bacterial infection"
         </a>
         .)
        </p>
        <p>
         The combination of iron overload, chelation therapy (which mobilizes iron), and immunosuppression (from functional asplenia and treatment with glucocorticoids) increases risk for iron-avid organisms such as
         <em>
          Yersinia enterocolitica
         </em>
         [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="local">
          'Excessive iron stores'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5937.html" rel="external">
          "Evaluation and management of fever in children and adults with sickle cell disease", section on 'Risk of life-threatening infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3708343383">
         <span class="h2">
          Emerging infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transfused individuals with SCD may be at particular risk for emerging transfusion-associated infections including babesiosis and malaria, for which specific laboratory testing is not performed (or performed on a limited basis). A high degree of suspicion is needed for early detection [
         <a href="#rid54">
          54,55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">
          "Blood donor screening: Laboratory testing", section on 'Emerging infectious disease agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H552970510">
         <span class="h1">
          HYPERVISCOSITY FOLLOWING SIMPLE TRANSFUSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood viscosity is determined by an interrelationship between total hemoglobin (Hb), percent sickle hemoglobin (Hb S), blood flow rate, white blood cell count, and other parameters. As the blood viscosity increases beyond a threshold, oxygen delivery decreases (even if the Hb level has been increased).
        </p>
        <p>
         Hyperviscosity is a risk in some individuals receiving simple transfusions; this is because simple transfusion can raise the total Hb but only marginally lower the percentage of Hb S. In SCD, there is an optimal balance of increasing Hb levels and viscosity while also increasing oxygen delivery.
        </p>
        <p>
         With a simple transfusion in individuals with SCD, increasing the Hb level will result in an increase in oxygen delivery up to a certain threshold, after which there is a decrease in the oxygen delivery with further increases in Hb. Based on in vitro studies and experts' clinical experience, the risk of decreased oxygen delivery is considered to be highest when the total Hb is &gt;10 g/dL and the Hb S is &gt;50 percent of total Hb [
         <a href="#rid8">
          8,56
         </a>
         ].
        </p>
        <p>
         Symptoms of hyperviscosity are nonspecific and related to the affected vascular bed. The literature does not describe many cases of hyperviscosity syndrome, in part because hyperviscosity syndrome complications in SCD are often unintended and potentially avoidable consequences of a transfusion therapy. Central nervous system-related injury is the most severe hyperviscosity sequela in children and adults with SCD. Hyperviscosity in SCD can be associated with the following complications:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dural venous thrombosis [
         <a href="#rid57">
          57
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebral infarcts
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebral hemorrhage [
         <a href="#rid58">
          58
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures with hypertension [
         <a href="#rid59">
          59
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Death [
         <a href="#rid58">
          58,60
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The major strategies for preventing hyperviscosity include using exchange transfusion rather than simple transfusion for individuals with Hb &gt;10 g/dL and Hb S &gt;50 percent of total Hb, and using phlebotomy for those with a post-transfusion Hb above 12 to 13 g/dL and Hb S &gt;50 percent. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Simple versus exchange transfusion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1979336330">
         <span class="h1">
          EXCESSIVE IRON STORES
         </span>
        </p>
        <p class="headingAnchor" id="H2848358221">
         <span class="h2">
          Scope of the problem
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite limiting transfusion to appropriate indications, many patients with SCD will develop excessive iron stores if chelation therapy or red blood cell (RBC) exchange transfusion is not used. Excess iron is a cause of significant morbidity in patients with SCD, especially as their longevity continues to increase with improved management and use of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         [
         <a href="#rid61">
          61-63
         </a>
         ]. Hepatic fibrosis and death from hemosiderosis-related cirrhosis of the liver can occur [
         <a href="#rid64">
          64-68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3990188026">
         <span class="h2">
          Prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preventing accumulation of excess iron is critical to prevent serious morbidity and mortality.
        </p>
        <p>
         The preferred method to attenuate excessive iron stores is automated RBC exchange, or to a lesser degree, manual exchange. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Simple versus exchange transfusion'
         </a>
         .)
        </p>
        <p>
         The American Society of Hematology (ASH) guidelines for SCD and transfusion support suggests using automated RBC exchange over simple transfusion or manual RBC exchange in patients receiving chronic transfusions [
         <a href="#rid8">
          8
         </a>
         ]. A shared decision-making model with the patient and family is recommended; this should consider patient age, patient preferences, need for a central venous access device, iron overload status, adherence with iron chelation, and the availability of compatible RBCs, especially in heavily alloimmunized individuals.
        </p>
        <p>
         Compared with simple transfusion, automated RBC exchange results in a smaller increase in ferritin. This was illustrated in a secondary analysis of the Silent Cerebral Infarct Trial (SIT), a stroke prevention trial that compared regular transfusions versus standard of care [
         <a href="#rid69">
          69
         </a>
         ]. The method of regular transfusion (simple transfusion, manual exchange transfusion, or automated exchange transfusion) was determined by the site investigators based on local resources and patient characteristics. A secondary analysis involving 83 participants who received monthly blood transfusion therapy for one year analyzed the effect of the transfusion method on ferritin levels (
         <a class="graphic graphic_figure graphicRef134782" href="/z/d/graphic/134782.html" rel="external">
          figure 1
         </a>
         ). Baseline ferritin levels were similar in all three groups, at approximately 100 to 200 ng/mL. After one year of transfusions, the median ferritin levels (and interquartile ranges [IQR]) were as follows [
         <a href="#rid69">
          69
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Simple transfusion – 1800 ng/mL (IQR, 1426 to 2204 ng/mL)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Manual exchange – 1530 ng/mL (IQR, 1205 to 1805 ng/mL)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Automated exchange – 355 ng/mL (IQR, 179 to 579 ng/mL)
        </p>
        <p>
        </p>
        <p>
         Only 9 participants received automated exchange transfusion, and the analysis only covered one year of transfusion therapy [
         <a href="#rid69">
          69
         </a>
         ]. Nevertheless, these data clearly show the benefit of automated exchange transfusion in attenuating iron overload compared with the other transfusion methods.
        </p>
        <p>
         The center of one of the authors no longer offers simple transfusions to patients who require monthly blood transfusions to maintain Hb S levels &lt;30 percent of total Hb. The patients receive either manual or automated exchange transfusions. Occasional patients will receive simple transfusions as a short-term measure or because a central line cannot be placed, but generally, they do not perform simple transfusions for &gt;12 months. This practice is informed by several cases of premature death in adolescents with SCD who received simple transfusions for many years coupled with non-adherence to chelation therapy.
        </p>
        <p>
         For those who receive regular, chronic simple transfusions, iron chelation therapy is an important component of the transfusion program because it prevents complications of iron deposition in organs, particularly in the liver. Long-term efficacy and safety studies on the effects of chelation on morbidity and mortality in individuals with SCD have not been completed, but existing data and multiple consensus reports recommend iron chelation therapy for transfusion iron overload [
         <a href="#rid70">
          70,71
         </a>
         ]. (See
         <a class="local">
          'Chelation therapy'
         </a>
         below.)
        </p>
        <p>
         In contrast to chelation, phlebotomy cannot be used to remove iron in transfusion-dependent individuals due to their baseline anemia; phlebotomy is useful only in the rare individual with SCD and a high baseline hemoglobin (Hb) concentration. In such cases, automated apheresis is effective in minimizing the iron burden and may prevent the need for chelation [
         <a href="#rid72">
          72-74
         </a>
         ]. Excess iron can be removed by phlebotomy following hematopoietic stem cell transplant, provided the post-transplant Hb concentration is sufficiently high to allow for a transient further decrease in Hb. (See
         <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">
          "Hematopoietic stem cell transplantation in sickle cell disease"
         </a>
         .)
        </p>
        <p>
         Other means of minimizing iron burden include [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restricting transfusions to appropriate indications. (See
         <a class="local">
          'Appropriate indications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Indications for transfusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optimal use of disease-modifying therapies. (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease", section on 'Indications and appropriate age to start therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease", section on 'FDA-approved agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1121811902">
         <span class="h2">
          Monitoring iron stores
         </span>
        </p>
        <p class="headingAnchor" id="H1336571629">
         <span class="h3">
          Serum ferritin concentration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The serum ferritin concentration is a useful test to monitor the status of iron stores, particularly by following the trend. Ferritin levels need to be serially measured at least every three to four months and must be drawn in the steady-state, separate from acute inflammatory or vaso-occlusive events. Ferritin is an acute-phase reactant and will become elevated during acute inflammatory events.
        </p>
        <p>
         We prefer to draw the ferritin levels with each blood draw at routine outpatient visits to monitor the trend for the individual, which is more representative of iron stores than a single ferritin measurement. Patients receiving chelation therapy have monitoring of serum ferritin level at every transfusion. Since the ferritin fluctuates, it is important to average three to five serial ferritin measurements before determining the direction in change of iron stores.
        </p>
        <p>
         We aim to maintain a serum ferritin value no greater than 1000 to 1500 ng/mL (no greater than 1000 to 1500 mcg/L). However, periodic monitoring of quantitative liver iron is important, as discussed below. (See
         <a class="local">
          'Liver'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4237564425">
         <span class="h3">
          Tissue iron stores
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optimal management of iron overload in SCD requires the periodic correlation of ferritin with tissue iron stores in the liver and sometimes the heart. (See
         <a class="local">
          'Liver'
         </a>
         below and
         <a class="local">
          'Heart'
         </a>
         below.)
        </p>
        <p>
         Additional evaluations for endocrine dysfunction may be appropriate (thyroid function, FSH and LH in females, testosterone in males).
        </p>
        <p class="headingAnchor" id="H4084384751">
         <span class="h4">
          Liver
         </span>
         <span class="headingEndMark">
          —
         </span>
         We measure liver iron stores noninvasively using magnetic resonance imaging (MRI) at the initiation of chelation therapy and every one to two years in chronically transfused patients [
         <a href="#rid8">
          8
         </a>
         ]. More frequent monitoring may be used if a potential decision is to be made about stopping chelation therapy. Conversely, in patients receiving chronic transfusion by red blood cell (RBC) exchange with a neutral or negative RBC balance and have a ferritin less than 1000 ng/mL, measurement of liver iron content every one to two years is not needed [
         <a href="#rid8">
          8
         </a>
         ]. We use non-invasive quantitative MRI to assess liver iron; regionally, different techniques to quantitate iron stores may be available. Quantitative MRI using R2 or R2* relaxometry or biomagnetic liver susceptometry (Ferritometer) are acceptable. The Ferriscan is a standardized, validated MRI method using R2 MRI that utilizes locally acquired data analyzed at a centralized facility that can be adapted to most MRI scanners. (See
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload", section on 'Noninvasive imaging (MRI)'
         </a>
         .)
        </p>
        <p>
         We prefer to use MRI to monitor iron status and adjust chelation for a number of reasons, including the lack of a clear correlation of steady-state ferritin levels with hepatic iron stores and the desire to avoid an invasive procedure [
         <a href="#rid64">
          64,75-77
         </a>
         ]. At least two studies found a poor correlation of serum ferritin with hepatic iron stores as determined by liver biopsy in patients who were receiving chronic transfusions [
         <a href="#rid64">
          64,77
         </a>
         ]. Furthermore, significant variability of the liver iron content may occur within the liver, such that a single needle biopsy may not be representative of the total liver iron content [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         We reserve liver biopsy for rare individuals with SCD in whom the MRI-based estimate of the liver iron content is inconsistent with the transfusion history or where there is concern regarding liver function (and assessment of liver histology is needed). Some curative therapy protocols may require a liver biopsy to assess for bridging fibrosis. However, the clinical utility of this indication for a liver biopsy is unclear, particularly in individuals with low liver iron content. (See
         <a class="medical medical_review" href="/z/d/html/3614.html" rel="external">
          "Methods to determine hepatic iron content"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H253101637">
         <span class="h4">
          Heart
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with SCD accumulate cardiac iron at a lower rate than patients with thalassemia but remain at risk for cardiac hemosiderosis. Cardiac iron cannot be predicted solely by liver iron stores. We generally reserve cardiac iron monitoring using T2* MRI of the heart for patients with a high iron burden (liver iron content &gt;15 mg/g dry weight for two years or more) or those with evidence of cardiac dysfunction or other end organ damage due to iron overload [
         <a href="#rid8">
          8,79-81
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">
          "Clinical utility of cardiovascular magnetic resonance imaging", section on 'Iron overload'
         </a>
         .)
        </p>
        <p>
         While improved chelation programs may stabilize patients with cardiac dysfunction, the root cause of excessive iron strokes must be addressed by a multidisciplinary team. Serious iron overload can result from nonadherence to therapy. Factors causing nonadherence, including lack of family/caregiver support and home infrastructure, must be addressed to have long-term improvement.
        </p>
        <p class="headingAnchor" id="H3540682547">
         <span class="h2">
          Chelation therapy
         </span>
        </p>
        <p class="headingAnchor" id="H679090469">
         <span class="h3">
          When to start chelation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initiation of chelation therapy in individuals with SCD depends upon the number of transfusions given, the degree of iron deposition in the liver and heart, the amount of hepatic and cardiac dysfunction present, and the type of transfusion regimen [
         <a href="#rid68">
          68,70,82
         </a>
         ]. Management by a multidisciplinary team that includes at least a medical social worker and a nurse case manager is optimal and should include staff familiar with the toxicity and compliance issues associated with iron chelation and prevention of organ injury.
        </p>
        <p>
         Generally, chelation therapy is started after one to two years of transfusion in chronically transfused individuals, when the serum ferritin exceeds at least 1000 to 1500 mcg/L (ng/mL) or the liver iron is &gt;3 to 5 mg/g dry weight. Often this correlates with a total transfusion burden of approximately 120 to 200 mL of transfused RBCs per kilogram, although in practice, calculating this volume may not be very helpful. A quality-of-care indicator from the American Academy of Pediatrics suggests that children receive chelation therapy to maintain a ferritin &lt;1500 ng/mL or liver iron &lt;7 mg/g dry weight [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
         The major challenge in using these criteria is that when patients transition to exchange transfusion from simple transfusion, the ferritin level typically falls below 1000 ng/mL after 12 months, but the tissue iron stores may still be high. We prefer to use annual liver MRI and initiate chelation if the liver iron is &gt;3 mg/g dry weight or if the serum ferritin is &gt;1000 ng/mL on two consecutive measurements.
        </p>
        <p>
         The targets used for iron chelation therapy are changing as better iron chelators become available. Studies addressing the long-term safety and efficacy of maintaining near normal iron stores have not been completed [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         Baseline testing prior to starting chelation includes audiology, ophthalmology, and pregnancy test in females.
        </p>
        <p class="headingAnchor" id="H3551484122">
         <span class="h3">
          Choice of chelating agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three iron chelating agents are available:
         <a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">
          deferiprone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          deferoxamine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          deferasirox
         </a>
         . For most patients, we use deferasirox because it is orally active and has a good therapeutic index (eg, benefit to toxicity ratio).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          Deferasirox
         </a>
         – Deferasirox (DFX; Exjade, Jadenu) is an orally available iron chelator that appears to have efficacy similar to
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          deferoxamine
         </a>
         in decreasing liver iron concentration [
         <a href="#rid85">
          85
         </a>
         ]. Exjade is a tablet that was approved in 2005 for individuals two years or older with iron overload. Jadenu is a powder formulation of the same drug that can be sprinkled on food, which is easier for young children. Concomitant use of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         does not appear to alter the efficacy, safety, or pharmacokinetics of deferasirox [
         <a href="#rid86">
          86
         </a>
         ]. The side effect profile of deferasirox appears to be tolerable in individuals with SCD. The major adverse events include gastrointestinal symptoms, a reversible, dose-dependent rise in serum creatinine, and occasional liver dysfunction. (See
         <a class="local">
          'Monitoring for adverse events'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">
          Deferiprone
         </a>
         – Deferiprone (DFP; Ferriprox) is an orally active iron chelator that was approved for use in sickle cell disease in 2021 [
         <a href="#rid87">
          87
         </a>
         ]. Its major side effect is the risk of agranulocytosis; therefore the FDA requires weekly neutrophil counts on all patients [
         <a href="#rid88">
          88
         </a>
         ]. Patients may also experience arthralgia and gastrointestinal symptoms, and hepatotoxicity has been reported [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          Deferoxamine
         </a>
         – Deferoxamine (DFO; Desferal) is effective and available but requires daily subcutaneous infusions that last for many hours, which often result in poor adherence to therapy. This agent can also be given intravenously for more rapid iron chelation. Since the half-life of DFO is extremely short (ie, minutes), the efficacy of DFO is determined by its duration of infusion as well as the dose.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2502696466">
         <span class="h3">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal dose of the chelating agent is determined by the patient's age, iron stores, the frequency of transfusions, and the presence of organ dysfunction. Persistently low ferritin levels (eg, below 500 ng/mL) in the face of regular chelation are not optimal for growing children and may be associated with increased toxicity.
        </p>
        <p>
         Most patients require modification of dosing based on response and organ function over time. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Deferasirox
         </strong>
         – The starting dose for oral
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          deferasirox
         </a>
         as Exjade is 20 mg/kg/day once daily. The dose is increased by 5 to 10 mg every three to six months based on iron stores. Toxicities such as skin rash, nausea, and diarrhea are dose related. These adverse events may be decreased by giving the same total dose twice a day, rather than once a day, and accompanied with food. The dosing for deferasirox as Jadenu is approximately 30 percent lower (rounded to the nearest whole tablet or sachet of granules) than for Exjade because of greater bioavailability [
         <a href="#rid90">
          90,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Exjade requires dispersion in a liquid
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Jadenu tablets can be swallowed whole but cannot be made into a suspension
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Jadenu granules can be sprinkled on soft foods
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Deferiprone
         </strong>
         – The standard dose of
         <a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">
          deferiprone
         </a>
         is 75 mg/kg/day, given as three doses of 25 mg/kg. After six months, it may be increased up to 100 mg/kg/day in non-responding or high-risk patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Deferoxamine
         </strong>
         – In general, in individuals without iron-induced cardiac dysfunction, the starting dose of
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          deferoxamine
         </a>
         is 30 mg/kg given daily over 8 to 12 hours, five days per week. This can be modified by 5 to 10 mg every three to six months depending on the individual patient's transfusion burden and iron status.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          Deferoxamine
         </a>
         with
         <a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">
          deferiprone
         </a>
         , sequentially or in combination, has been routinely used in high-risk patients with very high iron burden [
         <a href="#rid92">
          92
         </a>
         ]. In addition, the safety and efficacy of combining
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          deferasirox
         </a>
         and deferoxamine for severely affected individuals appears promising [
         <a href="#rid93">
          93-95
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7146.html" rel="external">
          "Iron chelators: Choice of agent, dosing, and adverse effects", section on 'Deferoxamine plus deferasirox'
         </a>
         .)
        </p>
        <p>
         Invariably, clinicians will identify a subgroup of children or adults with SCD with excessive liver iron stores (eg, &gt;15 mg/g dry weight, either by MRI or liver biopsy), without evidence of immediate cardiac arrhythmias or left ventricular dysfunction. In such situations, considerations should be made for alternative strategies for aggressive chelation, including hospitalization for intravenous chelation therapy and combination chelation. Inpatient chelation should be managed by (or in consultation with) a clinician with experience in this approach. Example dosing includes
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          deferoxamine
         </a>
         50 mg/kg over 24 hours for two days plus
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          deferasirox
         </a>
         20 to 40 mg/kg daily for two days.
         <a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">
          Deferiprone
         </a>
         may be added if heart failure or significant cardiac iron overload is present. Deferasirox may be added if liver iron content is very high.
        </p>
        <p>
         In the event that the patient has evidence of life-threatening cardiac arrhythmias or left ventricular dysfunction, we recommend extended inpatient hospitalization for chelation therapy with long-term combination chelation therapy. Chelation regimens for the management of cardiac dysfunction have been established for patients with thalassemia [
         <a href="#rid96">
          96-98
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6498.html" rel="external">
          "Acute iron poisoning", section on 'Deferoxamine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2951575851">
         <span class="h3">
          Monitoring for adverse events
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to monitoring iron stores during chelation (see
         <a class="local">
          'Monitoring iron stores'
         </a>
         above), we also perform the following testing for toxicity of the chelating agents:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Audiology
         </strong>
         – A formal audiology exam should be obtained prior to initiation of a chelator. A screening hearing exam should be performed in clinic every six months and a formal audiogram every 12 months. Those with new onset hearing loss or tinnitus should be evaluated. Hearing loss is most frequently identified with
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          deferoxamine
         </a>
         , especially at higher doses. Early detection of hearing loss followed by dose modification may result in reversal of damage. Irreversible hearing loss requiring hearing aids does occur [
         <a href="#rid99">
          99
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7146.html" rel="external">
          "Iron chelators: Choice of agent, dosing, and adverse effects", section on 'Side effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ophthalmology
         </strong>
         – Visual loss has been most clearly linked to
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          deferoxamine
         </a>
         , especially at high doses. A baseline and annual evaluation by an ophthalmologist should be performed. Individuals should be routinely questioned about visual acuity, changes in color, vision, and visual fields.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nephrology
         </strong>
         – With
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          deferasirox
         </a>
         , there is a dose-dependent rise in serum creatinine, which is reversible. Long-term follow-up studies of deferasirox for five years have shown a clinically acceptable safety profile, with no evidence of progressive or irreversible renal injury [
         <a href="#rid100">
          100
         </a>
         ]. Rare reports of renal failure and Fanconi syndrome have occurred in individuals receiving deferasirox, particularly in those not having dose adjustments for renal function abnormalities [
         <a href="#rid101">
          101-103
         </a>
         ]. Deferasirox may increase urinary calcium loss [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Creatinine/blood urea nitrogen (BUN), serum chemistry, and urine protein and creatinine should be monitored monthly in individuals on
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          deferasirox
         </a>
         and every three months in those on
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          deferoxamine
         </a>
         . We discontinue therapy immediately if the serum creatinine is greater than two times the upper limit of normal. Any patient who experiences a serum creatinine increase &gt;50 percent above baseline should have the dose held temporarily, and an increase in serum creatinine of 33 to 50 percent should prompt dose reduction. We temporarily hold the chelator if the urine protein/creatinine ratio is &gt;0.6 mg/mg (&gt;600 mg/g).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic
         </strong>
         – Those on
         <a class="drug drug_general" data-topicid="17092" href="/z/d/drug information/17092.html" rel="external">
          deferiprone
         </a>
         require a weekly complete blood count (CBC) to detect serious neutropenia/agranulocytosis; a neutrophil count below 1000 cells/microL (
         <a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">
          calculator 1
         </a>
         ) requires stopping the drug and reassessing future use. All individuals with fever who are on deferiprone require an immediate evaluation of their white blood cell count.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          Deferasirox
         </a>
         has been associated with neutropenia, agranulocytosis, worsening anemia, and thrombocytopenia, including fatal events. We hold therapy with deferasirox in individuals who develop cytopenias until the cause of the cytopenias has been determined. Deferasirox is contraindicated in patients with platelet counts below 50,000/microL [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Growth
         </strong>
         – Growth can sometimes be affected by chelators or confounded by excessive iron deposition [
         <a href="#rid106">
          106
         </a>
         ]. Ongoing measurements of height and weight velocity, including sitting height, should be performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal and liver function
         </strong>
         – Diarrhea, nausea and vomiting, and abdominal pain are common side effects with
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          deferasirox
         </a>
         , but these are usually mild and decrease with time; these effects appear to be less with the Jadenu formulation. Liver dysfunction has been seen in multicenter trials with deferasirox. Long-term follow-up studies of five years have not shown evidence of progressive or irreversible liver injury with deferasirox [
         <a href="#rid100">
          100
         </a>
         ]. However, post-marketing surveillance has identified hepatic failure as a complication in high-risk individuals, such as patients with pre-existing liver failure and hepatitis C.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          deferasirox
         </a>
         , serum transaminases and bilirubin should be monitored twice during the first month in individuals at high risk of liver disease (ie, those with hepatitis C or liver failure) after initiation of therapy with deferasirox and monthly afterward. For standard-risk individuals, hepatic enzymes should be monitored monthly with deferasirox and every three months with other chelators. We hold chelation therapy if the serum alanine aminotransferase (ALT, formerly called SGPT) is greater than five times the upper limit of normal.
        </p>
        <p>
        </p>
        <p>
         Other acute events that require immediate temporary withdrawal of chelation therapy include acute respiratory distress, Stevens-Johnson syndrome, and acute gastrointestinal bleeding.
         <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">
          Deferoxamine
         </a>
         has been associated with acute respiratory distress that can mimic acute chest syndrome. Gastrointestinal hemorrhage has been seen with
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          deferasirox
         </a>
         , especially in older adults with malignancies or thrombocytopenia [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
         Chelating agents may affect the growth of some microorganisms (eg,
         <em>
          Yersinia enterocolitica
         </em>
         ) and should be held temporarily in patients with fever or active infection until the patient becomes afebrile. (See
         <a class="local">
          'Bacterial infection'
         </a>
         above.)
        </p>
        <p>
         Decisions regarding discontinuation of the chelating agent or switching to a different chelator are made on a case-by-case basis depending on a variety of factors including the severity of the SCD complication, severity of the chelator toxicity, and availability and tolerability of alternative agents.
        </p>
        <p class="headingAnchor" id="H2696179701">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110843.html" rel="external">
          "Society guideline links: Sickle cell disease and thalassemias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1525740362">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (See
         <a class="medical medical_basics" href="/z/d/html/16730.html" rel="external">
          "Patient education: Sickle cell disease (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/88642.html" rel="external">
          "Patient education: When your child has sickle cell disease (The Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the basics topic (See
         <a class="medical medical_patient" href="/z/d/html/682.html" rel="external">
          "Patient education: Blood donation and transfusion (Beyond the Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2688779501">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/132604.html" rel="external">
          "Patient perspective: Sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1662577915">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoiding complications –
         </strong>
         Alloimmunization and excess iron stores are more frequent and severe in individuals with sickle cell disease (SCD) than the general population. Complications can be reduced by limiting transfusions to appropriate indications and using appropriate techniques. (See
         <a class="local">
          'Limiting transfusions to appropriate use'
         </a>
         above and
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alloimmunization
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For prevention, we match ABO, Rh (C, E, or C/e, E/e), and the Kell antigen K for all patients with SCD. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'RBC antigen matching'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         DHTRs may present with worsening anemia, fatigue, jaundice, dark urine, fever, and/or pain 3 to 14 days after transfusion. The direct antiglobulin test (DAT; Coombs test) may be negative or weakly positive. Evaluation for an antibody specificity should be performed. (See
         <a class="local">
          'Clinical features of immune hemolysis'
         </a>
         above and
         <a class="local">
          'Evaluation of immune hemolysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For an uncomplicated DHTR, we avoid further transfusion if possible and provide hydration and pain control as needed. If transfusions are required, we provide matched blood that lacks antigens identified in the DHTR evaluation. In addition to antigens listed above, we match for Jk
         <sup>
          a
         </sup>
         /Jk
         <sup>
          b
         </sup>
         , Fy
         <sup>
          a
         </sup>
         /Fy
         <sup>
          b
         </sup>
         , and S/s if time permits. (See
         <a class="local">
          'DHTRs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperhemolysis is a poorly understood form of bystander hemolysis that can cause life-threatening anemia. (See
         <a class="local">
          'Hyperhemolysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with SCD and severe DHTR or hyperhemolysis, we suggest immunosuppressive therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Common therapies include
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG). Watchful waiting is an alternative for milder hemolysis.
         <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">
          Eculizumab
         </a>
         may be used if prednisone and IVIG are ineffective. We also suggest erythropoietin (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – Parvovirus is not eliminated by screening or pathogen inactivation. Worsening anemia without reticulocytosis following transfusion is suggestive of parvovirus. Individuals with SCD are functionally asplenic and at risk for sepsis from bacterial infection. (See
         <a class="local">
          'Infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperviscosity
         </strong>
         – Hyperviscosity can occur if the hemoglobin (Hb) is &gt;10 g/dL and sickle hemoglobin (Hb S) is &gt;50 percent of total Hb. Prevention strategies include exchange transfusion rather than simple transfusion and phlebotomy if post-transfusion Hb is &gt;12 to 13 g/dL and Hb S is &gt;50 percent. (See
         <a class="local">
          'Hyperviscosity following simple transfusion'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Simple versus exchange transfusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Excess iron
         </strong>
         – Transfusion of &gt;15 to 20 RBC units (&gt;10 units in small children) can cause clinically significant iron overload (
         <a class="graphic graphic_figure graphicRef134782" href="/z/d/graphic/134782.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload", section on 'Transfusional iron overload'
         </a>
         and
         <a class="local">
          'Scope of the problem'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ferritin is measured between monthly and quarterly to provide immediate feedback about ferritin trends. We use liver magnetic resonance imaging (MRI)-based assessment of liver iron content to make a firm decision about clinical management. Liver MRI is done every one to two years in chronically transfused patients and before chelation. We generally reserve cardiac T2* MRI for patients with high iron burden, cardiac dysfunction, or other organ damage. (See
         <a class="local">
          'Serum ferritin concentration'
         </a>
         above and
         <a class="local">
          'Tissue iron stores'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chelation is generally started after one to two years of chronic transfusions and when the ferritin is &gt;1000 to 1500 ng/mL or liver iron is &gt;3 to 5 mg/g dry weight. (See
         <a class="local">
          'Chelation therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For most patients, we suggest
         <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">
          deferasirox
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Deferasirox is orally active and has a good benefit-to-toxicity ratio. (See
         <a class="local">
          'Choice of chelating agent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Ferritin is monitored at every transfusion and liver iron every one to two years. Monitoring for drug toxicity is individualized and may include ophthalmologic, auditory, hematologic, kidney, and liver function testing. (See
         <a class="local">
          'Monitoring for adverse events'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1357076732">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges extensive contributions of Donald H Mahoney, Jr, MD to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2015; 168:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med 2014; 371:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol 2013; 160:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballas SK. Meperidine for acute sickle cell pain in the emergency department: revisited controversy. Ann Emerg Med 2008; 51:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan MT. Use of meperidine as the analgesic of choice in treating pain from acute painful sickle cell crisis. Ann Emerg Med 2008; 51:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther 2002; 9:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood 2018; 131:2773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020; 4:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fasano RM, Chou ST. Red Blood Cell Antigen Genotyping for Sickle Cell Disease, Thalassemia, and Other Transfusion Complications. Transfus Med Rev 2016; 30:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heddle NM, Soutar RL, O'Hoski PL, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 1995; 91:1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evers D, Middelburg RA, de Haas M, et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. Lancet Haematol 2016; 3:e284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narbey D, Habibi A, Chadebech P, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol 2017; 92:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vidler JB, Gardner K, Amenyah K, et al. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol 2015; 169:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman S, Westhoff CM, Friedman DF, Chou ST. Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions. Transfusion 2019; 59:2282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olujohungbe A, Hambleton I, Stephens L, et al. Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol 2001; 113:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 120:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky EP. The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells. Immunohematology 2012; 28:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petz LD, Calhoun L, Shulman IA, et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion 1997; 37:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica 2011; 96:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion 2009; 49:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garratty G. Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion 1997; 37:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habibi A, Mekontso-Dessap A, Guillaud C, et al. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol 2016; 91:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pirenne F, Bartolucci P, Habibi A. Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment. Transfus Clin Biol 2017; 24:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos B, Portugal R, Nogueira C, Loureiro M. Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases. Transfusion 2015; 55:1394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aragona E, Kelly MJ. Hyperhemolysis in sickle cell disease. J Pediatr Hematol Oncol 2014; 36:e54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Win N, Sinha S, Lee E, Mills W. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfus Med Rev 2010; 24:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion 2008; 48:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reyes MA, Illoh OC. Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease. Immunohematology 2008; 24:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Win N, Doughty H, Telfer P, et al. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion 2001; 41:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darbari DS, Fasano RS, Minniti CP, et al. Severe Vaso-Occlusive Episodes Associated with Use of Systemic Corticosteroids in Patients with Sickle Cell Disease. J Natl Med Assoc 2008; 100:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strouse JJ, Takemoto CM, Keefer JR, et al. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer 2008; 50:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobota A, Graham DA, Neufeld EJ, Heeney MM. Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation. Pediatr Blood Cancer 2012; 58:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horton DP, Ferriero DM, Mentzer WC. Nontraumatic fat embolism syndrome in sickle cell anemia. Pediatr Neurol 1995; 12:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson K, Stastny JF, Rucknagel DL. Fat embolism syndrome associated with asthma and sickle cell-beta(+)-thalassemia. Am J Hematol 1994; 46:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92:3082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood 2016; 127:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unnikrishnan A, Pelletier JPR, Bari S, et al. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature. Transfusion 2019; 59:1907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlachaki E, Gavriilaki E, Kafantari K, et al. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Hemoglobin 2018; 42:339.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125166lbl.pdf (Accessed on May 21, 2020).
         </li>
         <li class="breakAll">
          https://www.cdc.gov/meningococcal/clinical/eculizumab.html (Accessed on May 21, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachmeyer C, Maury J, Parrot A, et al. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol 2010; 85:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meenan J, Hall R, Badle S, et al. Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: The experience so far. Transfusion 2022; 62:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee LE, Beeler BW, Graham BC, et al. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab. Transfusion 2020; 60:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivapalaratnam S, Linpower L, Sirigireddy B, et al. Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab. Br J Haematol 2019; 186:e212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hair PS, Heck TP, Carr DT, et al. Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease and the Role of the Classical Complement Pathway: A Case Report. J Hematol 2021; 10:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uhlmann EJ, Shenoy S, Goodnough LT. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion 2014; 54:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet 2013; 381:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Monnier O, Joseph L, Bodard S, Boudhabhay I. Hepato-splenic abscesses in a sickle cell disease patient. Am J Hematol 2022; 97:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herwaldt BL, Linden JV, Bosserman E, et al. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011; 155:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mace KE, Lucchi NW, Tan KR. Malaria Surveillance - United States, 2018. MMWR Surveill Summ 2022; 71:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmalzer EA, Lee JO, Brown AK, et al. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion 1987; 27:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciurea SO, Thulborn KR, Gowhari M. Dural venous sinus thrombosis in a patient with sickle cell disease: case report and literature review. Am J Hematol 2006; 81:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Royal JE, Seeler RA. Hypertension, convulsions, and cerebral haemorrhage in sickle-cell anaemia patients after blood-transfusions. Lancet 1978; 2:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warth JA. Hypertension and a seizure following transfusion in an adult with sickle cell anemia. Arch Intern Med 1984; 144:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serjeant G. Blood transfusion in sickle cell disease: a cautionary tale. Lancet 2003; 361:1659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charache S. Treatment of sickle cell anemia. Annu Rev Med 1981; 32:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010; 115:2354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006; 81:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol 2001; 38:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perronne V, Roberts-Harewood M, Bachir D, et al. Patterns of mortality in sickle cell disease in adults in France and England. Hematol J 2002; 3:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porter JB, Shah FT. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin North Am 2010; 24:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly S, Rodeghier M, DeBaun MR. Automated exchange compared to manual and simple blood transfusion attenuates rise in ferritin level after 1 year of regular blood transfusion therapy in chronically transfused children with sickle cell disease. Transfusion 2020; 60:2508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011; 364:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucania G, Vitrano A, Filosa A, Maggio A. Chelation treatment in sickle-cell-anaemia: much ado about nothing? Br J Haematol 2011; 154:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quirolo K. How do I transfuse patients with sickle cell disease? Transfusion 2010; 50:1881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HC, Dugan NP, Silber JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994; 83:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer ST, Quirolo K, Nishi K, et al. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher 1999; 14:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pippard MJ. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies. Acta Haematol 1987; 78:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karam LB, Disco D, Jackson SM, et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatr Blood Cancer 2008; 50:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villeneuve JP, Bilodeau M, Lepage R, et al. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol 1996; 25:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meloni A, Puliyel M, Pepe A, et al. Cardiac iron overload in sickle-cell disease. Am J Hematol 2014; 89:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter PB, Harmatz P, Vichinsky E. Iron metabolism and iron chelation in sickle cell disease. Acta Haematol 2009; 122:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006; 135:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program 2013; 2013:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang CJ, Kavanagh PL, Little AA, et al. Quality-of-Care Indicators for Children With Sickle Cell Disease. Pediatrics 2011; 128:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coates TD, Carson S, Wood JC, Berdoukas V. Management of iron overload in hemoglobinopathies: what is the appropriate target iron level? Ann N Y Acad Sci 2016; 1368:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky E, Torres M, Minniti CP, et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Am J Hematol 2013; 88:1068.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212269s001lbl.pdf (Accessed on May 03, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky E. Iron overload and iron chelation therapy in pediatric patients. US Hematology 2009; 2:64. Online access: http://www.touchbriefings.com/pdf/3324/elliott_vichinsky.pdf
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583.
          </a>
         </li>
         <li class="breakAll">
          http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021882s006lbl.pdf (Accessed on October 27, 2015).
         </li>
         <li class="breakAll">
          http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206910s001s003lbl.pdf (Accessed on October 27, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwiatkowski JL. Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med 2011; 2:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lal A, Sweeters N, Ng V, et al. Combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent thalassemia. Blood (ASH Annual Meeting Abstracts) 2010; 116:4269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lal A, Porter J, Sweeters N, et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis 2013; 50:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassinerio E, Orofino N, Roghi A, et al. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Blood Cells Mol Dis 2014; 53:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013; 128:281.
          </a>
         </li>
         <li class="breakAll">
          2012 Standards of Care Guidelines for Thalassemia. Published by Children's Hospital &amp; Research Center Oakland. http://hemonc.cho.org/thalassemia/treatment-guidelines-1.aspx#gsc.tab=0 and http://hemonc.cho.org/thalassemia/documents/SOCGuidelines2012.pdf (Accessed on October 08, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011; 154:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baum M. Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire. J Pediatr Hematol Oncol 2010; 32:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubourg L, Laurain C, Ranchin B, et al. Deferasirox-induced renal impairment in children: an increasing concern for pediatricians. Pediatr Nephrol 2012; 27:2115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grangé S, Bertrand DM, Guerrot D, et al. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant 2010; 25:2376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong P, Polkinghorne K, Kerr PG, et al. Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bone 2016; 85:55.
          </a>
         </li>
         <li class="breakAll">
          http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf (Accessed on March 07, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135:574.
          </a>
         </li>
         <li class="breakAll">
          http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021882s021lbl.pdf (Accessed on August 03, 2015).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 128123 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25256676" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25140956" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23215650" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18206563" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Meperidine for acute sickle cell pain in the emergency department: revisited controversy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18206552" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Use of meperidine as the analgesic of choice in treating pain from acute painful sickle cell crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11782820" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Meperidine: a critical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29724898" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31985807" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27345938" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Red Blood Cell Antigen Genotyping for Sickle Cell Disease, Thalassemia, and Other Transfusion Complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8547111" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27264038" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2342522" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11552063" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28924974" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25753472" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31021439" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2207318" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11380455" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22563085" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22646146" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9111275" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The sickle cell hemolytic transfusion reaction syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21330322" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Delayed hemolytic transfusion reaction in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19413729" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9111271" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Severe reactions associated with transfusion of patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27348613" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28669521" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25677578" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23619113" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hyperhemolysis in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19962576" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18373500" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19852130" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11274584" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hyperhemolytic transfusion reaction in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28643632" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Severe Vaso-Occlusive Episodes Associated with Use of Systemic Corticosteroids in Patients with Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17849474" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21674766" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7748367" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Nontraumatic fat embolism syndrome in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8037190" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Fat embolism syndrome associated with asthma and sickle cell-beta(+)-thalassemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8107739" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9787142" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25203083" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26758914" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30768787" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30626228" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30626228" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30626228" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20029943" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35092617" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: The experience so far.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31642065" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31368112" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33643505" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease and the Role of the Classical Complement Pathway: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23692505" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23352054" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35567777" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Hepato-splenic abscesses in a sickle cell disease patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21893613" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Transfusion-associated babesiosis in the United States: a description of cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36048717" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Malaria Surveillance - United States, 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3590284" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16550522" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Dural venous sinus thrombosis in a patient with sickle cell disease: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/82175" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Hypertension, convulsions, and cerebral haemorrhage in sickle-cell anaemia patients after blood-transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6703831" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Hypertension and a seizure following transfusion in an adult with sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12747923" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Blood transfusion in sickle cell disease: a cautionary tale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7013661" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Treatment of sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11206959" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19903897" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10891433" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16924640" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Circumstances of death in adult sickle cell disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11206962" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Progression of iron overload in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11960397" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Patterns of mortality in sickle cell disease in adults in France and England.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21075283" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32812667" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Automated exchange compared to manual and simple blood transfusion attenuates rise in ferritin level after 1 year of regular blood transfusion therapy in chronically transfused children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21226580" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Iron-chelating therapy for transfusional iron overload.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21707578" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Chelation treatment in sickle-cell-anaemia: much ado about nothing?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20663110" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : How do I transfuse patients with sickle cell disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8111053" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10540366" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8416302" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3120473" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17457853" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8878778" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Variability in hepatic iron concentration measurement from needle-biopsy specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24664847" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Cardiac iron overload in sickle-cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19907155" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Iron metabolism and iron chelation in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17010049" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24319218" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Consequences and management of iron overload in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21844055" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Quality-of-care indicators for children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27186942" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17233848" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23946212" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23946212" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Iron overload and iron chelation therapy in pediatric patients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12763939" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12763939" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12763939" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22287873" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent thalassemia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23151373" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24846580" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10666195" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23775258" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Cardiovascular function and treatment inβ-thalassemia major: a consensus statement from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23775258" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Cardiovascular function and treatment inβ-thalassemia major: a consensus statement from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3485251" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21592110" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20686423" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22527533" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20466673" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Acute renal failure and Fanconi syndrome due to deferasirox.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26802257" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26802257" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17054676" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
